Chimeric antigen receptor (CAR) T-cell therapy has transformed the field of immuno-oncology providing a novel approach to treating certain blood cancers. As innovation progresses with the design of next-generation chimeric receptors and a better understanding of the tumor microenvironment, CAR-T therapy has the potential to also revolutionize therapies for treating solid tumors.
Whether you are looking to characterize scFv binding capabilities of your chimeric receptor, assess vector transduction efficiency of your CAR construct, measure T-cell proliferation and toxicity, or assess effector cell function of your CAR-T therapy, we have the solutions to fit your needs. Learn more in this flyer about the products designed to support your CAR-T research!